apomorphine has been researched along with Parkinsonian Disorders in 155 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.29) | 18.7374 |
| 1990's | 2 (1.29) | 18.2507 |
| 2000's | 77 (49.68) | 29.6817 |
| 2010's | 67 (43.23) | 24.3611 |
| 2020's | 7 (4.52) | 2.80 |
| Authors | Studies |
|---|---|
| Goudarzvand, M; Hajikhani, R; Jafari, F; Qorbani, M; Solati, J | 1 |
| Bulgakova, NV; Gonchar, OO; Kopyak, BS; Kostyukov, AI; Mankivska, OP; Maznychenko, AV; Mishchenko, IV; Prylutskyy, YI; Ritter, U; Sokolowska Vereshchaka, IV; Tomiak, T | 1 |
| Choy, YB; Lee, SH; Lim, J; Paek, SH; Park, CG; Park, HR; Park, HW; Park, M | 1 |
| Farmer, K; Hayley, S; Rowe, EM; Thompson, AM | 1 |
| Costa, G; Marongiu, J; Morelli, M; Serra, M; Simola, N | 1 |
| Hur, J; Kim, J; Kim, MC; Lee, CH; Li, H; Tran, HNK; Yang, HO | 1 |
| Antipova, V; Hawlitschka, A; Holzmann, C; Witt, M; Wree, A | 1 |
| Liu, L; Wang, X; Zhang, L; Zhang, W | 1 |
| Andersson, DR; Borkar, N; Holm, R; Mu, H; Müllertz, A; Yang, M | 1 |
| Jia, J; Li, L; Li, M; Su, W; Wang, K; Wang, X | 1 |
| Altschüler, J; Beck, MH; Haumesser, JK; Kühn, AA; Kühn, J; Nikulin, VV; van Riesen, C | 1 |
| Ando, K; Inoue, R; Kawai, K; Nishime, C; Nishinaka, E; Tsutsumi, H; Urano, K | 1 |
| Chen, X; Jia, L; Liu, H; Shi, L; Xie, J | 1 |
| Airavaara, M; Bäck, S; Huotarinen, A; Julku, U; Laakso, A; Männistö, PT; Penttinen, AM; Piepponen, TP; Saarma, M; Tuominen, R; Voutilainen, MH | 1 |
| Bjarkam, CR; Christensen, AB; Ettrup, KS; Orlowski, D; Sørensen, JCH | 1 |
| Du, CX; Liu, J; Sun, YN; Wang, HS; Wang, Y; Yao, L; Zhang, GJ; Zhang, L | 1 |
| Du, CX; Guo, Y; Liu, J; Lv, SX; Zhang, J; Zhang, QJ | 1 |
| Andrade, GM; Calou, IBF; Costa, RO; Lima, FAV; Lima, LAR; Lopes, MJP; Neves, KRT; Viana, GSB | 1 |
| Lin, L; Lin, R; Wu, B; Yan, M; Zheng, Z | 1 |
| Antipova, V; Hawlitschka, A; Holzmann, C; Wree, A | 1 |
| Avcı, B; Balcı, H; Bilge, SS; Bozkurt, A; Günaydın, C; Önger, ME | 1 |
| Berzuino, MB; Campos, ACP; Domenici, RA; Fonoff, ET; Hernandes, MS; Maciel, ST; Pagano, RL | 1 |
| Ai, Y; Andersen, AH; Gash, DM; Gerhardt, GA; Grondin, R; Guduru, Z; Hardy, P; Quintero, JE; Zhang, Z | 1 |
| Jalali-Nadoushan, M; Roghani, M | 1 |
| Karuppagounder, SS; Madathil, SK; Mohanakumar, KP | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Higashi, Y; Miyazaki, I; Namba, M; Ogawa, N | 1 |
| Hacksell, U; Hubbard, D; McFarland, K | 1 |
| Chen, L; Feng, J; Han, LN; Li, LB; Liu, J; Sun, YN; Wang, T; Wang, Y; Zhang, L; Zhang, QJ | 1 |
| Kinney, JW; Landers, MR; van Breukelen, F | 1 |
| Arneson, LC; Crow, JM; Faltesek, KA; Fine, JM; Forsberg, AC; Frey, WH; Hanson, LR; Mohan, KG; Renner, DB; Wong, JC | 1 |
| Banerjee, M; Mohanakumar, KP; Nthenge-Ngumbau, DN; Tripathy, D; Verma, P | 1 |
| Capozzo, A; Mattei, C; Mazzone, P; Scarnati, E; Vitale, F | 1 |
| Eidi, A; Roghani, M; Rohani, AH; Zare, K | 1 |
| Jiaming, M; Niu, C | 1 |
| Auburger, G; Bez, F; Brehm, N; Carlsson, T; Cenci, MA; Gispert, S; Kern, B | 1 |
| Abe, H; Arimori, K; Ikeda, T; Ishida, Y; Koganemaru, G; Yasuda, K | 1 |
| Chen, L; Guo, Y; Han, LN; Li, LB; Liu, J; Sun, YN; Wang, Y; Zhang, L; Zhang, QJ; Zhang, YM | 1 |
| Bagga, V; Dunnett, SB; Fricker, RA | 1 |
| Barnett, DG; Ciucci, M; Doll, EJ; Grant, LM; Leverson, G | 1 |
| Sharma, S; Singh, S; Taliyan, R | 1 |
| Deng, Y; Lu, J; Ma, H; Qing, H; Sun, F | 1 |
| Chen, NH; Chu, SF; Li, J; Liu, Y; Song, LK; Sun, JD; Yuan, YH | 1 |
| Hiratochi, M; Ijiro, T; Kaidoh, K; Oana, F; Suzuki, T; Tsuchioka, A; Yamauchi, Y | 1 |
| Benabid, AL; Chabrol, C; Costecalde, T; Cretallaz, C; Darlot, F; Johnstone, DM; Massri, NE; Mitrofanis, J; Moro, C; Reinhart, F; Stone, J; Torres, N | 1 |
| Kokare, DM; Shelkar, GP; Subhedar, NK; Upadhya, MA | 1 |
| Alipour Heidari, M; Dargahi, T; Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Mahmudi, M; Piri, H | 1 |
| Barkholt, P; Fabricius, K; Hansen, HH; Jelsing, J; Knudsen, LB; Mikkelsen, JD; Pyke, C; Vrang, N | 1 |
| Cash, D; Mesquita, M; Simmons, C; Sumiyoshi, A; Vernon, AC; Westphal, R; Williams, SC; Wood, TC | 1 |
| Bahna, SG; Carriere, CH; Kang, NH; Niles, LP | 1 |
| Antkiewicz-Michaluk, L; Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T | 1 |
| Chen, L; Du, CX; Liu, J; Lv, SX; Sun, YN; Wang, T; Wang, Y; Zhang, J; Zhang, L; Zhang, QJ | 1 |
| Glavan, G | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Daniels, WM; Di Chiara, G; Morelli, M; Schallert, T; Simola, N | 1 |
| Bi, J; Gu, S; Huang, H; Wen, T; Yao, Y | 1 |
| Ballion, B; Chetrit, J; Frenois, F; Gonon, F; Murer, MG; Zold, CL | 1 |
| Ali, U; Chen, L; Gui, ZH; Liu, J; Wang, S; Wang, Y; Zhang, QJ | 1 |
| Jia, J; Li, B; Liu, L; Pan, Y; Sun, Z; Wang, H; Wang, X; Yu, F; Zhang, L | 1 |
| Bilici, N; Gören, B; Korfali, E; Mimbay, Z; Oğul, E; Zarifoğlu, M | 1 |
| Achaval, M; Anselmo-Franci, JA; Bagatini, PB; de David, C; Delattre, AM; Ferraz, AC; Iagher, F; Kiss, A; Marroni, NA; Rigon, P; Szawka, RE; Xavier, LL | 1 |
| Johansson, SM; Modo, MM; Vernon, AC | 1 |
| Dong, WL; Kong, Y; Xue, SR; Yang, XX | 1 |
| Jackson, MJ; Jenner, PG; Johnston, LC; Jones, CA; McCreary, AC; Rose, S; Smith, LA; van Scharrenburg, G | 1 |
| Bordet, R; Destée, A; Duhamel, A; Kreisler, A; Vanbesien-Mailliot, C | 1 |
| Cao, X; Chen, C; Huang, J; Jia, M; Liang, Z; Lin, Z; Sun, S; Wang, T; Xiong, J; Xiong, N; Zhang, Z | 1 |
| Baluchnejadmojarad, T; Jalali-Nadoushan, MR; Khalili, M; Kiasalari, Z; Niknam, A; Roghani, M | 1 |
| Kunselman, AR; Lieu, CA; Manyam, BV; Subramanian, T; Venkiteswaran, K | 1 |
| Cumming, P; Kjaerby, C; Knudsen, GM; Palner, M | 1 |
| Chen, JJ; Chen, LH; Chiang, PT; Hsieh, TH; Lee, HY | 1 |
| Ali, U; Chen, L; Gui, ZH; Liu, J; Wang, T; Wang, Y | 1 |
| Ma, Z; Wang, J; Wang, R; Xie, J | 1 |
| Domínguez-Marrufo, LE; García-Macedo, JA; Hernandez-Ramírez, H; Hernández-Téllez, B; Ibarra-Guerrero, P; López-Martínez, IE; Sánchez-Cervantes, I; Santiago, J; Santiago-Jacinto, P; Valverde-Aguilar, G; Vergara-Aragón, P | 1 |
| Faraji, A; Fraidouni, N; Haghdoost-Yazdi, H; Jahanihashemi, H; Sarookhani, M | 1 |
| Cao, Y; Ge, Y; Hu, X; Yin, P; Zhou, X | 1 |
| Chen, Y; Dai, FR; Du, XP; Li, M; Yang, QD | 1 |
| An, CN; Pu, XP; Sun, SY | 1 |
| Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M | 1 |
| Eitan, R; Goelman, G; Gordon, N; Sourani, D | 1 |
| Dong, C; Jin, G; Qin, J; Tan, X; Tian, M; Zhang, L; Zhao, H; Zhu, H | 1 |
| Bonifati, V; Oostra, BA; Severijnen, LA; Willemsen, R; Zhao, T; Zondervan-van der Linde, H | 1 |
| Arbuthnott, GW; Chan, DC; Ke, Y; Ko, H; Li, Q; Qian, ZM; Yung, KK; Yung, WH | 1 |
| Ahmad, AS; Doré, S; Maruyama, T; Narumiya, S | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Barone, P; Cicarelli, G; De Michele, G; Pellecchia, MT; Pizzolato, G | 1 |
| Barreto, WJ; Blum, D; Britto, LR; Gaziri, LC; Ponzoni, S | 1 |
| Caudle, WM; Cohen, AD; Miller, GW; Schallert, T; Tillerson, JL; Zigmond, MJ | 1 |
| Matsumura, M | 1 |
| Chambers, JW; Fletcher, PJ; Hebb, MO; Lang, AE; Lozano, AM | 1 |
| Blinov, DV; Chekhonin, VP; Dmitrieva, TB; Lazarenko, IP; Lebedev, SV; Savchenko, EA; Volodin, NN | 1 |
| Bucan, M; Fetsko, LA; Hranilovic, D; Wang, Y; Xu, R | 1 |
| Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| Gonzalez, CL; Vergara-Aragon, P; Whishaw, IQ | 1 |
| Aniello, MS; De Mari, M; Defazio, G; Lamberti, P; Zenzola, A | 1 |
| Archer, T; Fredriksson, A | 1 |
| Birumachi, J; Hirabayashi, H; Ishizaka, S; Kanda, S; Nakase, H; Nishimura, F; Nonaka, M; Ouji, Y; Sakaki, T; Shiroi, A; Yokota, H; Yoshikawa, M | 1 |
| Gerlach, M; Halliday, GM; Heinemann, T; Henderson, JM; Watson, S | 1 |
| Henderson, JM; Watson, SH | 1 |
| Chang, MY; Chung, HY; Kim, JY; Kim, YC; Koh, HC; Lee, JY; Lee, SH; Lee, YS; McKay, R; Son, H; Studer, L | 1 |
| Balcioglu, A; Tarazi, FI; Zhang, K | 1 |
| Bjarkam, C; Cumming, P; Gillings, NM; Gjedde, A; Jensen, SB | 1 |
| Hong, J; Junxia, X; Ming, Q; Wenfang, C | 1 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| STRUPPLER, A; VON UEXKULL, T | 1 |
| ENGLAND, AC; SCHWAB, RS | 1 |
| Ceballos-Baumann, A | 1 |
| Hidaka, M; Kim, DS; Oi, S | 1 |
| Del Bel, EA; Gomes, MZ | 1 |
| Frederickson, J; Meshul, CK; Moore, C; Touchon, JC | 1 |
| De Groote, C; Fischer, G; Jenner, P; Kemp, JA; Klockgether, T; Löschmann, PA; Smith, L; Wüllner, U | 1 |
| Kellaway, L; Mabandla, M; Russell, VA; St Clair Gibson, A | 1 |
| Kim, WK; Kim, YB; Kim, YJ; Lee, SG; Lee, U; Paik, DJ; Park, CW; Yoo, CJ; Yoo, HT; Yoo, YM | 1 |
| Happe, S; Meller, J; Paulus, W; Sommer, M; Trenkwalder, C | 1 |
| Schmidt, WJ; Srinivasan, J | 1 |
| Mandel, S; Maor, G; Youdim, MB | 1 |
| Bibbiani, F; Chase, TN; Costantini, LC; Patel, R | 1 |
| Agrawal, AK; Ahmad, AS; Ahmad, M; Ansari, MA; Chaturvedi, RK; Ishrat, T; Islam, F; Khan, MB; Saleem, S; Yousuf, S | 1 |
| Bloom, DC; Boat, K; Castañeda, E; Fleming, S; Moffett, J; Paquette, MA; Stachowiak, EK; Stachowiak, MK | 1 |
| Abela, D; Allbutt, H; Dabholkar, V; Henderson, JM; Jovic, J; Quinlivan, M; Schleimer, SB | 1 |
| Glavan, G; Zivin, M | 1 |
| Ding, JH; Hu, G; Hu, LF; Liu, SY; Sun, T; Sun, YH; Wang, S; Wu, J; Zhang, Y | 1 |
| Hedrich, K; Kann, M; Kis, B; Klein, C; Kömpf, D; Pramstaller, PP; Schwinger, E | 1 |
| Howells, FM; Kellaway, LA; Mabandla, MV; Russell, VA | 1 |
| Ando, K; Higuchi, M; Inaji, M; Maeda, J; Nagai, Y; Nariai, T; Obayashi, S; Ohno, K; Okano, H; Okauchi, T; Suhara, T; Yoshizaki, T | 1 |
| Agari, T; Date, I; Hayase, H; Ji Yuan, W; Kameda, M; Kobayashi, K; Matsui, T; Miyoshi, Y; Muraoka, K; Shingo, T; Yasuhara, T | 1 |
| Ishizaka, S; Nishimura, F; Sakaki, T; Toriumi, H; Yoshikawa, M | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V | 1 |
| Köllensperger, M; Poewe, W; Reindl, M; Stefanova, N; Wenning, GK | 1 |
| Carlson, NE; Gunzler, SA; Meshul, CK; Nutt, JG; Shakil, S | 1 |
| Canteras, NS; Da Cunha, C; Ferro, MM; Hipólide, D; Martinez, GR; Tufik, S; Vital, MA; Wietzikoski, EC | 1 |
| Hedlund, E; Isacson, O; Kim, KS; Lardaro, T; Ludwig, W; Pruszak, J; Viñuela, A | 1 |
| Abuirmeileh, A; Biggs, CS; Harkavyi, A; Kingsbury, AE; Lever, R; Whitton, PS | 1 |
| Agnati, LF; Aguirre, JA; Andbjer, B; Cintra, A; Finnman, UB; Fuxe, K; Hagman, M; Höglund, C; Möller, A | 1 |
| Grünblatt, E; Mandel, S; Youdim, MB | 1 |
| Albanese, A; Colosimo, C; Moro, E; Rossi, P; Tonali, P | 1 |
| Allen, C; Meshul, CK | 1 |
| Aoi, M; Date, I; Ohmoto, T; Tomita, S | 2 |
| Cui, X; Li, XJ; Ma, XJ; Sun, AM; Wang, LN; Wang, ZF; Xue, YL; Zhong, DG; Zhu, K | 1 |
| Gassen, M; Gross, A; Grünblatt, E; Mandel, S; Youdim, MB | 1 |
| Freund, RK; Gerhardt, GA; Giardina, KE; Granholm, AC; Moorhead, JW; Palmer, MR; van Horne, CG | 1 |
| Bell, KP; Choi, PK; Clarkson, ED; Esplen, JE; Freed, CR; Heidenreich, KA; Zawada, WM | 1 |
| Behzadi, G; Roghani, M | 1 |
| Friess, E; Holsboer, F; Kuempfel, T; Rupprecht, R; Schmid, D; Trenkwalder, C; Uhr, M; Winkelmann, J | 1 |
| Bezard, E; Bioulac, B; Boraud, T; Gross, CE | 1 |
| Jacques, DB; Kopyov, O; Olds, ME | 1 |
| Aceves, J; Erlij, D; Floran, B; Galvan, A | 1 |
| Gutknecht, C | 1 |
| Benabid, AL; Benazzouz, A; Bouali-Benazzouz, R; Gao, D; Ni, Z | 1 |
| Xie, JX; Zhao, ZQ; Zhou, Y | 1 |
| Eoh, W; Hong, SC; Kim, JH; Kim, JS; Lee, JI; Lee, WY; Nam, DH; Park, K; Shin, HJ | 1 |
| Charles, KJ; Gray, J; Hunter, AJ; Jenner, P; Medhurst, AD; Reavill, C; Shale, JA; Zeng, BY | 1 |
| Cicchetti, F; Hennen, J; Isacson, O; Moore, AE | 1 |
| Lu, JQ; Stoessl, AJ | 1 |
| Gerhardt, GA; Granholm, AC; Hoffer, BJ; Lintz, E; McGrath, J; Quintero, EM | 1 |
| Cornfeldt, ML; Marchionini, D; Potter, EM; Subramanian, T | 1 |
4 review(s) available for apomorphine and Parkinsonian Disorders
| Article | Year |
|---|---|
Experimental parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Apomorphine; Basal Ganglia; Bicuculline; Cerebral Cortex; Disease Models, Animal; Dopamine; Dopamine Agonists; Electrocoagulation; GABA Antagonists; Globus Pallidus; Humans; Models, Neurological; MPTP Poisoning; Muscle Rigidity; Neurotoxins; Parkinsonian Disorders; Primates; Substance-Related Disorders; Substantia Nigra; Tegmentum Mesencephali; Thalamus | 2001 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apomorphine; Chelating Agents; Dopamine Agonists; Humans; Iron; Parkinson Disease; Parkinsonian Disorders; Reactive Oxygen Species | 2000 |
[Parkinson therapy 2001, especially apomorphine in idiopathic Parkinson syndrome].
Topics: Antiparkinson Agents; Apomorphine; Electric Stimulation Therapy; Humans; Neurologic Examination; Parkinsonian Disorders; Prognosis; Substantia Nigra | 2001 |
2 trial(s) available for apomorphine and Parkinsonian Disorders
| Article | Year |
|---|---|
Acute challenge with apomorphine and levodopa in Parkinsonism.
Topics: Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Sensitivity and Specificity | 2000 |
Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Apomorphine; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hydrocortisone; Male; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Prolactin | 2001 |
149 other study(ies) available for apomorphine and Parkinsonian Disorders
| Article | Year |
|---|---|
Pycnogenol ameliorates motor function and gene expressions of NF-ƙB and Nrf2 in a 6-hydroxydopamine-induced experimental model of Parkinson's disease in male NMRI mice.
Topics: Animals; Antioxidants; Apomorphine; Dose-Response Relationship, Drug; Flavonoids; Gene Expression Regulation; Male; Mice; Neuroprotective Agents; NF-E2-Related Factor 2; NF-kappa B; Oxidopamine; Parkinsonian Disorders; Plant Extracts | 2022 |
C60 fullerenes increase the intensity of rotational movements in non‑anesthetized hemiparkinsonic rats.
Topics: Animals; Antioxidants; Apomorphine; Female; Fullerenes; Motor Activity; Muscle Fatigue; Muscle, Skeletal; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Stereotaxic Techniques | 2020 |
Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinson's disease rat model.
Topics: Administration, Oral; Animals; Apomorphine; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Drug; Down-Regulation; Inflammation; Infusion Pumps, Implantable; Infusions, Parenteral; Male; Neovascularization, Physiologic; Neurogenesis; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase; Ubiquinone | 2020 |
Erythropoietin modulates striatal antioxidant signalling to reduce neurodegeneration in a toxicant model of Parkinson's disease.
Topics: Animals; Apomorphine; Brain; Cell Shape; Corpus Striatum; Dopamine; Erythropoietin; Humans; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroglia; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Pilot Projects; Recombinant Proteins; Single-Blind Method; Video Recording | 2020 |
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Ultrasonic Waves; Vocalization, Animal | 2021 |
Extract of Polygala tenuifolia, Angelica tenuissima, and Dimocarpus longan Reduces Behavioral Defect and Enhances Autophagy in Experimental Models of Parkinson's Disease.
Topics: Angelica; Animals; Apomorphine; Autophagy; Cell Line, Tumor; Corpus Striatum; Dopaminergic Neurons; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Neuroblastoma; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Polygala; Random Allocation; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Sapindaceae; Saponins; Substantia Nigra; Triterpenes; Tyrosine 3-Monooxygenase | 2021 |
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.
Topics: Amphetamine; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Botulinum Toxins, Type A; Corpus Striatum; Disease Models, Animal; Injections; Male; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar | 2021 |
Time course study of fractional anisotropy in the substantia nigra of a parkinsonian rat model induced by 6-OHDA.
Topics: Animals; Apomorphine; Diffusion Tensor Imaging; Disease Progression; Dopamine Agonists; Gliosis; Immunohistochemistry; Magnetic Resonance Imaging; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2017 |
Efficacy of oral lipid-based formulations of apomorphine and its diester in a Parkinson's disease rat model.
Topics: Administration, Oral; Animals; Apomorphine; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Drug Liberation; Emulsions; Esters; Half-Life; Lipids; Male; Oxidopamine; Parkinsonian Disorders; Prodrugs; Rats; Rats, Sprague-Dawley | 2017 |
The effect of electroacupuncture on proteomic changes in the motor cortex of 6-OHDA Parkinsonian rats.
Topics: Animals; Apomorphine; Blotting, Western; Chromatography, High Pressure Liquid; Dopamine Agonists; Electroacupuncture; Immunohistochemistry; Male; Mass Spectrometry; Medial Forebrain Bundle; Motor Activity; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Proteome; Proteomics; Random Allocation; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2017 |
Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
Topics: Animals; Apomorphine; Basal Ganglia; Cerebral Cortex; Dose-Response Relationship, Drug; Levodopa; Male; Nerve Net; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar | 2017 |
Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Area Under Curve; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Methamphetamine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2017 |
The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Anthracenes; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agonists; Dopaminergic Neurons; Infusions, Intraventricular; KCNQ Potassium Channels; Male; Motor Activity; Muscle Rigidity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Potassium Channel Blockers; Rats, Wistar; Substantia Nigra | 2018 |
Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Combined Modality Therapy; Corpus Striatum; Deep Brain Stimulation; Disease Progression; Dopamine Agonists; Humans; Male; Motor Activity; Nerve Growth Factors; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Recombinant Proteins; Tyrosine 3-Monooxygenase | 2018 |
Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Topics: Amphetamine; Animals; Apomorphine; Biophysics; Central Nervous System Stimulants; Corpus Striatum; Deep Brain Stimulation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Functional Laterality; Magnetic Resonance Imaging; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Substantia Nigra; Swine; Swine, Miniature; Sympatholytics; Tyrosine 3-Monooxygenase | 2018 |
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Endocannabinoids; Glycerides; Levodopa; Male; Metabolome; Metabolomics; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats, Sprague-Dawley | 2018 |
Involvement of prelimbic 5-HT
Topics: Animals; Anxiety; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Enzyme Inhibitors; Exploratory Behavior; Functional Laterality; Male; Maze Learning; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin Agents; Sympatholytics | 2018 |
Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Encephalitis; Exploratory Behavior; Lipid Peroxidation; Male; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Stereotyped Behavior; Swimming; Sympatholytics; Tyrosine 3-Monooxygenase; Vitamin D | 2018 |
Expression of magnesium transporter SLC41A1 in the striatum of 6-hydroxydopamine-induced parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Cation Transport Proteins; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; Gene Expression; Magnesium; Magnesium Sulfate; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; RNA, Messenger; Tyrosine 3-Monooxygenase | 2018 |
Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior.
Topics: Animals; Apomorphine; Behavior, Animal; Botulinum Toxins, Type A; Corpus Striatum; Donepezil; Injections; Male; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Rats, Wistar | 2018 |
Effects of agomelatine in rotenone-induced Parkinson's disease in rats.
Topics: Acetamides; Animals; Apomorphine; Apoptosis; Brain; Cell Count; Corpus Striatum; Hypokinesia; Male; Neurons; Oxidation-Reduction; Parkinsonian Disorders; Proteins; Rats; Rotarod Performance Test; Rotation; Rotenone | 2019 |
Parkinson's disease and pain: Modulation of nociceptive circuitry in a rat model of nigrostriatal lesion.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; Hot Temperature; Hydroxydopamines; Male; Nerve Net; Nociception; Pain; Pain Threshold; Parkinsonian Disorders; Physical Stimulation; Rats; Rats, Wistar; Substantia Nigra | 2019 |
Validations of apomorphine-induced BOLD activation correlations in hemiparkinsonian rhesus macaques.
Topics: Animals; Apomorphine; Dopamine Agonists; Female; Macaca mulatta; Magnetic Resonance Imaging; Motor Cortex; Oxygen Consumption; Parkinsonian Disorders | 2019 |
Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Malondialdehyde; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rotation; Substantia Nigra; Thioctic Acid | 2013 |
Sodium salicylate protects against rotenone-induced parkinsonism in rats.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Cyclooxygenase Inhibitors; Dopamine; Dose-Response Relationship, Drug; Electron Transport Complex I; Glutathione; Hydroxyl Radical; Male; Neurons; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Sodium Salicylate; Substantia Nigra; Superoxide Dismutase; Uncoupling Agents | 2013 |
Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-parkinsonian models.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Dopamine; Immunohistochemistry; Levodopa; Melanocytes; Mice; Monophenol Monooxygenase; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation | 2013 |
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
Topics: Amphetamine; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Clozapine; Dopamine; Dose-Response Relationship, Drug; Male; Parkinsonian Disorders; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Urea | 2013 |
The theta-related firing activity of parvalbumin-positive neurons in the medial septum-diagonal band of Broca complex and their response to 5-HT1A receptor stimulation in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Apomorphine; Desipramine; Diagonal Band of Broca; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Parvalbumins; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Substantia Nigra; Theta Rhythm | 2014 |
Forced exercise before or after induction of 6-OHDA-mediated nigrostriatal insult does not mitigate behavioral asymmetry in a hemiparkinsonian rat model.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Forelimb; Functional Laterality; Male; Oxidopamine; Parkinsonian Disorders; Physical Conditioning, Animal; Psychomotor Performance; Rats; Rats, Long-Evans; Stereotyped Behavior; Substantia Nigra | 2014 |
Intranasally-administered deferoxamine mitigates toxicity of 6-OHDA in a rat model of Parkinson׳s disease.
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Apomorphine; Deferoxamine; Dopamine Agonists; Dopaminergic Neurons; Functional Laterality; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Photomicrography; Rats, Long-Evans; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
Regenerative therapy in experimental parkinsonism: mixed population of differentiated mouse embryonic stem cells, rather than magnetically sorted and enriched dopaminergic cells provide neuroprotection.
Topics: Adrenergic Agents; Amphetamine; Animals; Apomorphine; Brain; Cell Differentiation; Disease Models, Animal; Dopamine; Embryonic Stem Cells; Functional Laterality; Magnetics; Male; Medial Forebrain Bundle; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation | 2014 |
Continuous stimulation of the pedunculopontine tegmental nucleus at 40 Hz affects preparative and executive control in a delayed sensorimotor task and reduces rotational movements induced by apomorphine in the 6-OHDA parkinsonian rat.
Topics: Animals; Apomorphine; Deep Brain Stimulation; Disease Models, Animal; Dopamine Agonists; Executive Function; Male; Movement; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Psychomotor Performance; Rats; Rats, Wistar; Reaction Time; Treatment Outcome | 2014 |
The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat.
Topics: Animals; Antioxidants; Apomorphine; Cell Count; Coumaric Acids; Dopaminergic Neurons; Iron; Lipid Peroxidation; Male; Mesencephalon; Nerve Tissue Proteins; Neuroprotective Agents; Nitrites; Oxidopamine; Parkinsonian Disorders; Phytotherapy; Random Allocation; Rats; Rats, Wistar; Stereotyped Behavior; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Tyrosine 3-Monooxygenase | 2015 |
Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson's disease.
Topics: Animals; Apomorphine; Corpus Striatum; Dopaminergic Neurons; Female; Immunohistochemistry; Locomotion; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Nerve Growth Factors; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Sprague-Dawley; Rotation | 2015 |
A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.
Topics: alpha-Synuclein; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Humans; Locomotion; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mutation, Missense; Nerve Tissue Proteins; Parkinsonian Disorders; Phosphorylation; Point Mutation; Post-Synaptic Density; Prions; Promoter Regions, Genetic; Protein Processing, Post-Translational; Stereotyped Behavior; Substantia Nigra; Transgenes | 2015 |
Pramipexole reduces parkinsonian tremor induced by pilocarpine infusion in the rat striatum.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzothiazoles; Disease Models, Animal; Infusions, Intraventricular; Injections, Intraperitoneal; Male; Parkinsonian Disorders; Pilocarpine; Pramipexole; Rats; Rats, Sprague-Dawley; Ventral Striatum | 2015 |
Activation of serotonin(2C) receptors in the lateral habenular nucleus increases the expression of depression-related behaviors in the hemiparkinsonian rat.
Topics: Action Potentials; Adrenergic Agents; Animals; Apomorphine; Depression; Disease Models, Animal; Dopamine Agonists; Exploratory Behavior; Food Preferences; Functional Laterality; Habenula; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin Agents; Substantia Nigra; Sucrose; Swimming | 2015 |
The 6-OHDA mouse model of Parkinson's disease - Terminal striatal lesions provide a superior measure of neuronal loss and replacement than median forebrain bundle lesions.
Topics: Animals; Apomorphine; Corpus Striatum; Dextroamphetamine; Dopamine Agonists; Dopamine Uptake Inhibitors; Dopaminergic Neurons; Dose-Response Relationship, Drug; Embryonic Stem Cells; Female; Medial Forebrain Bundle; Mice, 129 Strain; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rotation | 2015 |
Relationships among rat ultrasonic vocalizations, behavioral measures of striatal dopamine loss, and striatal tyrosine hydroxylase immunoreactivity at acute and chronic time points following unilateral 6-hydroxydopamine-induced dopamine depletion.
Topics: Acute Disease; Animals; Apomorphine; Chronic Disease; Corpus Striatum; Dopamine; Dopamine Agonists; Forelimb; Functional Laterality; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Long-Evans; Severity of Illness Index; Tyrosine 3-Monooxygenase; Ultrasonics; Vocalization, Animal | 2015 |
Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain-Derived Neurotrophic Factor; Butyric Acid; Corpus Striatum; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Hippocampus; Histamine Antagonists; Histone Deacetylases; Male; Motor Activity; Neuroimmunomodulation; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Tumor Necrosis Factor-alpha | 2015 |
Comparison between α-synuclein wild-type and A53T mutation in a progressive Parkinson's disease model.
Topics: Age Factors; alpha-Synuclein; Amino Acid Substitution; Animals; Apomorphine; Brain; Disease Models, Animal; Dopaminergic Neurons; Immunohistochemistry; Male; Mutant Proteins; Mutation, Missense; Parkinsonian Disorders; Phosphorylation; Protein Aggregation, Pathological; Rats; Rats, Transgenic; Rats, Wistar; Recombinant Proteins; Torsion Abnormality | 2015 |
Environment-contact administration of rotenone: A new rodent model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Apomorphine; Body Weight; Brain; Disease Progression; Dopamine; Dopamine Agonists; Enteric Nervous System; Environmental Exposure; Housing, Animal; Male; Mice, Inbred C57BL; Motor Activity; Muscle, Skeletal; Neurons; Olfactory Perception; Parkinsonian Disorders; Rotenone; Tyrosine 3-Monooxygenase | 2015 |
Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Azepines; Benzothiazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Ergolines; Indoles; Injections, Intraventricular; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pramipexole; Quinolines; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2015 |
Intracranial application of near-infrared light in a hemi-parkinsonian rat model: the impact on behavior and cell survival.
Topics: Animals; Apomorphine; Cell Survival; Dopamine Agonists; Dopaminergic Neurons; Dose-Response Relationship, Radiation; Feasibility Studies; Immunohistochemistry; Low-Level Light Therapy; Male; Mesencephalon; Movement; Optical Fibers; Oxidopamine; Parkinsonian Disorders; Phototherapy; Prostheses and Implants; Rats, Wistar; Tyrosine 3-Monooxygenase | 2016 |
CART modulates the effects of levodopa in rat model of Parkinson's disease.
Topics: Animals; Antibodies; Antiparkinson Agents; Apomorphine; Brain; Dopamine Agonists; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Levodopa; Male; Movement; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2016 |
Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation.
Topics: 4-Aminopyridine; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Functional Laterality; Male; Mental Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Postural Balance; Potassium Channel Blockers; Rats; Rats, Wistar; Tetraethylammonium; Thiazolidinediones | 2016 |
Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Body Weight; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopaminergic Neurons; Glucagon-Like Peptide-1 Receptor; Liraglutide; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |
Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system.
Topics: Animals; Apomorphine; Atrophy; Brain; Dopamine Agonists; Dopaminergic Neurons; Functional Laterality; Gray Matter; Immunohistochemistry; Magnetic Resonance Imaging; Male; Motor Activity; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2016 |
Altered melatonin MT
Topics: Animals; Apomorphine; Blotting, Western; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; Fluorescent Antibody Technique; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polymerase Chain Reaction; Random Allocation; Rats, Sprague-Dawley; Receptor, Melatonin, MT1; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |
The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
Topics: Acetylcysteine; Amphetamine; Animals; Apomorphine; Benzazepines; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Functional Laterality; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Raclopride; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation | 2017 |
Involvement of lateral habenula α1 subunit-containing GABA
Topics: Action Potentials; Animals; Apomorphine; Depression; Dopamine Agonists; GABA Antagonists; GABA-A Receptor Agonists; Habenula; Male; Muscimol; Neural Inhibition; Neurons; Oxidopamine; Parkinsonian Disorders; Picrotoxin; Prefrontal Cortex; Rats, Sprague-Dawley; Receptors, GABA-A; Serotonin | 2017 |
Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Functional Laterality; Gene Expression; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Synaptotagmins; Time Factors | 2008 |
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Catechols; Corpus Striatum; Dynorphins; Electron Transport Complex IV; Enkephalins; Gene Expression; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nitriles; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Subthalamus | 2008 |
Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Enzyme Inhibitors; Functional Laterality; Male; Metyrapone; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Restraint, Physical; Rotarod Performance Test; Rotation; Time Factors | 2009 |
Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Movement; Cells, Cultured; Disease Models, Animal; Dopamine; Genetic Therapy; Maze Learning; Medial Forebrain Bundle; Motor Activity; Nerve Degeneration; Neurogenesis; Neurons; Neurotrophin 3; Oxidopamine; Parkinsonian Disorders; Rats; Stem Cell Transplantation; Stem Cells; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2009 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2009 |
Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agonists; Electrophysiology; Excitatory Amino Acid Antagonists; Immunohistochemistry; Male; Microelectrodes; Neurons; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine; Receptors, Metabotropic Glutamate; Tyrosine 3-Monooxygenase | 2009 |
Electro-acupuncture stimulation improves motor disorders in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Disease Models, Animal; Dopamine; Dyskinesias; Electroacupuncture; Enkephalins; Glutamate Decarboxylase; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Parkinsonian Disorders; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Substance P; Tyrosine 3-Monooxygenase | 2009 |
Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apomorphine; Aspirin; Behavior, Animal; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Immunohistochemistry; Meloxicam; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sympatholytics; Thiazines; Thiazoles | 2009 |
Evaluation of chronic omega-3 fatty acids supplementation on behavioral and neurochemical alterations in 6-hydroxydopamine-lesion model of Parkinson's disease.
Topics: Animals; Apomorphine; Brain; Cell Membrane; Disease Models, Animal; Dopamine; Dopamine Agonists; Fatty Acids, Omega-3; Lipid Peroxidation; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Treatment Outcome; Tyrosine 3-Monooxygenase | 2010 |
Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
Topics: Acetylcysteine; alpha-Synuclein; Animals; Apomorphine; Corpus Striatum; Cysteine Proteinase Inhibitors; Disease Models, Animal; Dopamine; Dopamine Agonists; Iron; Magnetic Resonance Imaging; Male; Mesencephalon; Motor Activity; Neurons; Parkinsonian Disorders; Random Allocation; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2010 |
Therapeutic effect of human amniotic epithelial cell transplantation into the lateral ventricle of hemiparkinsonian rats.
Topics: Amnion; Animals; Apomorphine; Chromatography, High Pressure Liquid; Epithelial Cells; Female; Homovanillic Acid; Humans; Immunohistochemistry; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2009 |
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Topics: Animals; Apomorphine; Benzoxazoles; Callithrix; Dopamine Agonists; Female; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Sulpiride | 2010 |
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Bezafibrate; Cell Count; Disease Models, Animal; Drug Interactions; Exploratory Behavior; Fenofibrate; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Statistics, Nonparametric; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2010 |
Long-term efficacy and safety of human umbilical cord mesenchymal stromal cells in rotenone-induced hemiparkinsonian rats.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apomorphine; Brain; Carbocyanines; Cell Differentiation; Cell Movement; Corpus Striatum; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Intermediate Filament Proteins; Locomotion; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Neoplasm Proteins; Nerve Tissue Proteins; Nestin; Neurons; Parkinsonian Disorders; Pentylenetetrazole; Phosphopyruvate Hydratase; Rats; Rats, Sprague-Dawley; Rotation; Rotenone; Staining and Labeling; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase; Umbilical Cord; Ventral Tegmental Area | 2010 |
Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism.
Topics: Administration, Oral; Animals; Anthocyanins; Antiparkinson Agents; Apomorphine; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Lipid Peroxidation; Male; Mesencephalon; Neurons; Neuroprotective Agents; Nitric Oxide; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Statistics, Nonparametric; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2010 |
A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Forelimb; Mucuna; Oxidopamine; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Rotation; Time Factors; Tyrosine 3-Monooxygenase; Vibrissae | 2010 |
Effects of unilateral 6-OHDA lesions on [3H]-N-propylnorapomorphine binding in striatum ex vivo and vulnerability to amphetamine-evoked dopamine release in rat.
Topics: Amphetamine; Animals; Apomorphine; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Uptake Inhibitors; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2011 |
Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion.
Topics: Analysis of Variance; Animals; Apomorphine; Disease Models, Animal; Disease Progression; Functional Laterality; Gait Disorders, Neurologic; Male; Medial Forebrain Bundle; Movement; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Rats; Rats, Wistar; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase; Videotape Recording | 2011 |
Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.
Topics: Action Potentials; Animals; Apomorphine; Cell Count; Disease Models, Animal; Dopamine Agonists; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2011 |
L-type Cav1.2 calcium channel is involved in 6-hydroxydopamine-induced neurotoxicity in rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Calcium Channel Blockers; Calcium Channels, L-Type; Dopamine; Dopaminergic Neurons; Drug Interactions; Female; Nifedipine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substantia Nigra; Sympatholytics | 2012 |
Tio2-dopamine complex implanted unilaterally in the caudate nucleus improves motor activity and behavior function of rats with induced hemiparkinsonism.
Topics: Animals; Apomorphine; Caudate Nucleus; Dopamine; Male; Motor Activity; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Titanium | 2011 |
High intake of folic acid or complex of B vitamins provides anti-Parkinsonism effect: no role for serum level of homocysteine.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Area Under Curve; Disease Models, Animal; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Folic Acid; Homocysteine; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Statistics, Nonparametric; Stereotyped Behavior; Vitamin B Complex | 2012 |
Chronic high-frequency stimulation therapy in hemiparkinsonian rhesus monkeys using an implanted human DBS system.
Topics: Animals; Apomorphine; Cerebral Angiography; Deep Brain Stimulation; Disease Models, Animal; Electrodes, Implanted; Follow-Up Studies; Functional Laterality; Gliosis; Macaca mulatta; Male; Movement; Parkinsonian Disorders; Rotation; Subthalamic Nucleus; Time Factors | 2013 |
Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease.
Topics: Adenoviridae; Animals; Antiparkinson Agents; Apomorphine; Apoptosis; Cell Line; Corpus Striatum; Dopaminergic Neurons; Humans; Kidney; Macrophages; Male; Mice; Microglia; Motor Activity; Nitric Oxide Synthase Type II; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Small Interfering; Sympatholytics; Tumor Suppressor Protein p53 | 2012 |
DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Dopaminergic Neurons; Drug Evaluation, Preclinical; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Ion Channels; Leupeptins; Male; Microinjections; Mitochondrial Membrane Transport Proteins; Mitochondrial Proteins; Mitochondrial Uncoupling Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Oncogene Proteins; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Protein Deglycase DJ-1; Rats; Rats, Sprague-Dawley; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2012 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2012 |
The habenula couples the dopaminergic and the serotonergic systems: application to depression in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Depression; Dopamine; Habenula; Hippocampus; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Parkinsonian Disorders; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Serotonin; Swimming; Thalamus | 2012 |
Transplantation of neural stem cells co-transfected with Nurr1 and Brn4 for treatment of Parkinsonian rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Green Fluorescent Proteins; Male; Nerve Tissue Proteins; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinsonian Disorders; POU Domain Factors; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Time Factors; Transfection; Tyrosine 3-Monooxygenase | 2013 |
Dopaminergic neuronal loss and dopamine-dependent locomotor defects in Fbxo7-deficient zebrafish.
Topics: Animals; Apomorphine; Body Patterning; Brain; Disease Models, Animal; Domperidone; Dopamine; Dopamine Antagonists; Exons; Expressed Sequence Tags; F-Box Proteins; Humans; Immunohistochemistry; In Situ Hybridization; Introns; Locomotion; Neurons; Parkinsonian Disorders; Phenotype; Protein Structure, Tertiary; RNA, Messenger; Zebrafish | 2012 |
Therapeutic deep brain stimulation in Parkinsonian rats directly influences motor cortex.
Topics: Action Potentials; Adrenergic Agents; Afferent Pathways; Animals; Antiparkinson Agents; Apomorphine; Biophysics; Brain Mapping; Deep Brain Stimulation; Disease Models, Animal; Electrodes, Implanted; Electroencephalography; Evoked Potentials, Motor; Functional Laterality; Locomotion; Male; Medial Forebrain Bundle; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Statistics as Topic; Subthalamic Nucleus | 2012 |
PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.
Topics: Animals; Apomorphine; Dinoprostone; Dopamine Agonists; Dopaminergic Neurons; Injections; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Targeted Therapy; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Receptors, Prostaglandin E, EP1 Subtype; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
Paradoxical response to apomorphine in a case of atypical parkinsonism.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Treatment Failure | 2002 |
Clearance of manganese from the rat substantia nigra following intra-nigral microinjections.
Topics: Animals; Apomorphine; Cell Death; Chlorides; Dopamine; Dopamine Agonists; Gliosis; Immunohistochemistry; Male; Manganese; Manganese Compounds; Manganese Poisoning; Metabolic Clearance Rate; Microinjections; Neurons; Parkinsonian Disorders; Rats; Rats, Inbred Strains; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surgical; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Forelimb; Homovanillic Acid; Membrane Glycoproteins; Membrane Transport Proteins; Movement; Nerve Tissue Proteins; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Physical Exertion; Rats; Rats, Long-Evans; Restraint, Physical; Tyrosine 3-Monooxygenase; Vesicular Biogenic Amine Transport Proteins | 2002 |
Neonatal ablation of the nigrostriatal dopamine pathway does not influence limb development in rats.
Topics: Animals; Animals, Newborn; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Extremities; Leg Bones; Leg Length Inequality; Mesencephalon; Motor Cortex; Neural Pathways; Neurons; Parkinsonian Disorders; Pyramidal Tracts; Radiography; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Comparison of the efficacy of cell preparations from embryonic ventral mesencephalon of various prenatal age transplanted intrastriatally to rats with 6-OHDA-induced Parkinsonism.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Dopamine; Fetal Tissue Transplantation; Male; Mesencephalon; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2002 |
Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Clozapine; Dopamine Agonists; Dose-Response Relationship, Drug; Hallucinogens; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Parkinsonian Disorders; Protein Isoforms; Raclopride; Receptors, Dopamine D2 | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index | 2003 |
A novel skilled-reaching impairment in paw supination on the "good" side of the hemi-Parkinson rat improved with rehabilitation.
Topics: Animals; Apomorphine; Behavior Control; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Feeding Behavior; Female; Forelimb; Functional Laterality; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Recovery of Function; Substantia Nigra; Supination | 2003 |
Frequency of apraxia of eyelid opening in the general population and in patients with extrapyramidal disorders.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Apraxias; Blepharospasm; Dystonia; Eyelids; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2002 |
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Guanfacine; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-2; Synaptic Transmission; Yohimbine | 2003 |
Potential use of embryonic stem cells for the treatment of mouse parkinsonian models: improved behavior by transplantation of in vitro differentiated dopaminergic neurons from embryonic stem cells.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Culture Techniques; Cell Differentiation; Cells, Cultured; Dopamine Agonists; Green Fluorescent Proteins; Immunohistochemistry; Indicators and Reagents; Luminescent Proteins; Male; Mice; Mice, Inbred Strains; Neurons; Parkinsonian Disorders; Rotation; Stem Cells | 2003 |
Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Death; Disease Models, Animal; Dopamine; Female; Functional Laterality; Neostriatum; Neurons; Orientation; Oxidopamine; Parkinsonian Disorders; Perceptual Disorders; Postural Balance; Posture; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2003 |
Convulsive and postural effects of lesioning the mid-substantia nigra pars reticulata in naïve and 6-hydroxydopamine lesioned rats.
Topics: Animals; Apomorphine; Behavior, Animal; Cortical Synchronization; Disease Models, Animal; Dopamine Agonists; Female; Functional Laterality; Kainic Acid; Motor Activity; Oxidopamine; Parkinsonian Disorders; Perceptual Disorders; Posture; Rats; Rats, Sprague-Dawley; Rotation; Seizures; Substantia Nigra | 2003 |
Dopaminergic neuronal differentiation from rat embryonic neural precursors by Nurr1 overexpression.
Topics: Animals; Antigens, Differentiation; Apomorphine; Ascorbic Acid; Astrocytes; Cell Differentiation; Cells, Cultured; Disease Models, Animal; DNA-Binding Proteins; Dopamine; Gene Expression; Gestational Age; Graft Survival; Male; Mesencephalon; Motor Activity; Neurons; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Retroviridae; Stem Cell Transplantation; Stem Cells; Transcription Factors; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2003 |
Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study.
Topics: Afferent Pathways; Amphetamine; Animals; Apomorphine; Binding, Competitive; Carrier Proteins; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Extracellular Matrix; Membrane Glycoproteins; Membrane Transport Proteins; Microdialysis; Neostriatum; Nerve Tissue Proteins; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Synaptic Transmission | 2003 |
Kinetics of the uptake and distribution of the dopamine D(2,3) agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy and MPTP-treated Göttingen miniature pigs.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Brain; Carbon Radioisotopes; Kinetics; Metabolic Clearance Rate; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3; Reference Values; Swine, Miniature; Tissue Distribution | 2003 |
Dopamine release rather than content in the caudate putamen is associated with behavioral changes in the iron rat model of Parkinson's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Caudate Nucleus; Chlorides; Deferoxamine; Disease Models, Animal; Dopamine; Drug Administration Routes; Female; Ferric Compounds; Iron; Iron Chelating Agents; Parkinsonian Disorders; Putamen; Rats; Rats, Sprague-Dawley | 2003 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
[Studies of mechanism of action of apormorphine on Parkinson's tremor].
Topics: Apomorphine; Humans; Parkinson Disease; Parkinsonian Disorders; Tremor | 1953 |
Problems in the treatment of Parkinsonism by analeptics.
Topics: Amphetamine; Amphetamines; Apomorphine; Central Nervous System Stimulants; Humans; Parkinson Disease; Parkinsonian Disorders; Pentylenetetrazole | 1956 |
"Hydrocephalus-parkinsonism complex": progressive hydrocephalus as a factor affecting extrapyramidal tract disorder-an experimental study.
Topics: Animals; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Disease Models, Animal; Drug Interactions; Functional Laterality; Hydrocephalus; Kaolin; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Time Factors | 2004 |
Effects of electrolytic and 6-hydroxydopamine lesions of rat nigrostriatal pathway on nitric oxide synthase and nicotinamide adenine dinucleotide phosphate diaphorase.
Topics: Adrenergic Agents; Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Electric Injuries; Functional Laterality; Immunohistochemistry; Injections, Intraventricular; Male; Microelectrodes; NADPH Dehydrogenase; Nitric Oxide Synthase; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2003 |
Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.
Topics: Animals; Apomorphine; Corpus Striatum; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2004 |
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phenols; Piperidines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate | 2004 |
Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle.
Topics: Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Physical Conditioning, Animal; Rats; Rats, Long-Evans; Running; Substantia Nigra; Sympathectomy, Chemical; Sympatholytics | 2004 |
Neurotrophic factor in the treatment of Parkinson disease.
Topics: Animals; Apomorphine; Astrocytes; Cell Differentiation; Cell Division; Cells, Cultured; Female; Fibroblast Growth Factor 2; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; Nerve Growth Factors; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Stem Cells; Visual Cortex | 2003 |
Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder.
Topics: Antiparkinson Agents; Apomorphine; Basal Ganglia; Dyskinesia, Drug-Induced; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon | 2005 |
Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Dextroamphetamine; Drug Synergism; Idazoxan; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin; Sympatholytics | 2005 |
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apomorphine; Catechin; Disease Models, Animal; Free Radicals; Iron; Iron Chelating Agents; Lewy Bodies; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Substantia Nigra; Synucleins; Ubiquitin | 2004 |
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Implants; Dyskinesias; Inflammation; Injections, Subcutaneous; Macaca fascicularis; Male; Movement; Parkinsonian Disorders; Polyvinyls; Recovery of Function; Steroids | 2005 |
Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Catecholamines; Disease Models, Animal; Dopamine Agonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Ginkgo biloba; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Immunohistochemistry; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plant Extracts; Psychomotor Performance; Rats; Rats, Wistar; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Thiobarbituric Acid Reactive Substances; Tyrosine 3-Monooxygenase | 2005 |
Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate.
Topics: Animals; Apomorphine; Astrocytes; Behavioral Research; Brain Tissue Transplantation; Corpus Striatum; Denervation; Dopamine; Male; Motor Activity; Motor Skills; Oxidopamine; Parkinsonian Disorders; Perceptual Disorders; Rats; Rats, Inbred F344; Recovery of Function; Rotation; Stereotyped Behavior; Substantia Nigra; Treatment Outcome | 2005 |
Behavioural effects of parafascicular thalamic lesions in an animal model of parkinsonism.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Choice Behavior; Disease Models, Animal; Female; Grooming; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piloerection; Posture; Rats; Rats, Sprague-Dawley; Reaction Time; Reinforcement, Psychology; Stereotyped Behavior; Thalamic Nuclei; Vibrissae | 2005 |
Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Female; Gene Expression; Gene Expression Regulation; In Situ Hybridization; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Isoforms; Rats; Rats, Wistar; RNA, Messenger; Rotation; Substantia Nigra; Synaptotagmins; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Apomorphine; Astrocytes; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Extracellular Fluid; Glutamic Acid; Male; Microdialysis; Neurotransmitter Agents; Parkinsonian Disorders; Pinacidil; Potassium Channels, Inwardly Rectifying; Presynaptic Terminals; Propylamines; Rats; Rats, Sprague-Dawley; Synaptic Transmission | 2006 |
Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications.
Topics: Age of Onset; Antiparkinson Agents; Apomorphine; Basal Ganglia; Calcinosis; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Levodopa; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinsonian Disorders | 2005 |
Stress reduces the neuroprotective effect of exercise in a rat model for Parkinson's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Dopamine; Dopamine Agonists; Functional Laterality; Male; Medial Forebrain Bundle; Oxidopamine; Parkinsonian Disorders; Physical Conditioning, Animal; Random Allocation; Rats; Rats, Long-Evans; Running; Statistics, Nonparametric; Stress, Psychological; Sympathectomy, Chemical; Sympatholytics; Tyrosine 3-Monooxygenase | 2005 |
Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Functional Laterality; Male; Methamphetamine; Movement; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2005 |
Control of dopamine-secretion by Tet-Off system in an in vivo model of parkinsonian rat.
Topics: Animals; Antiporters; Apomorphine; Bacterial Proteins; Behavior, Animal; Cell Transplantation; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Doxycycline; Female; Gene Expression Regulation; Humans; Immunohistochemistry; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rotarod Performance Test; Time Factors; Tyrosine 3-Monooxygenase | 2006 |
Use of differentiating embryonic stem cells in the Parkinsonian mouse model.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Culture Techniques; Cell Differentiation; Cell Line; Dopamine; Embryo, Mammalian; Male; Mice; Parkinsonian Disorders; Pluripotent Stem Cells; Stem Cell Transplantation; Tyrosine 3-Monooxygenase | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior | 2006 |
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Functional Laterality; Levodopa; Male; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2007 |
Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice.
Topics: Animals; Apomorphine; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Down-Regulation; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neural Inhibition; Parkinsonian Disorders | 2007 |
Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission.
Topics: Analysis of Variance; Animals; Apomorphine; Brain Damage, Chronic; Disease Models, Animal; Dopamine; Dopamine Agonists; Functional Laterality; Locomotion; Male; Motor Activity; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Severity of Illness Index; Statistics, Nonparametric; Substantia Nigra | 2008 |
Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Cell Differentiation; Cell Survival; Embryonic Stem Cells; Flow Cytometry; Genes, Reporter; Green Fluorescent Proteins; Homeodomain Proteins; Hydroxydopamines; Mesencephalon; Mice; Mitosis; Motor Activity; Parkinsonian Disorders; Rats; Stem Cell Transplantation; Transcription Factors; Transplantation, Heterologous | 2008 |
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Endotoxins; Exenatide; Glucagon-Like Peptide-1 Receptor; Levodopa; Locomotion; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Substantia Nigra; Tyrosine 3-Monooxygenase; Venoms | 2008 |
Subchronic toluene exposure in low concentrations produces signs of reduced dysfunction in the 6-hydroxydopamine lesioned nigrostriatal dopaminergic system of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Denervation; Dopamine; Injections, Intraventricular; Male; Motor Activity; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Toluene; Tyrosine 3-Monooxygenase | 1999 |
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agents; Ferritins; Iron; Lipid Peroxidation; Mice; Nerve Degeneration; NF-kappa B; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats; Tyrosine 3-Monooxygenase | 1999 |
Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Topics: Animals; Apomorphine; Denervation; Dopamine Agonists; Dopamine Antagonists; Glutamic Acid; Haloperidol; Immunohistochemistry; Male; Motor Cortex; Neostriatum; Nerve Degeneration; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Time Factors | 2000 |
The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Topics: Animals; Apomorphine; Axons; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Functional Laterality; Glial Cell Line-Derived Neurotrophic Factor; Immunohistochemistry; Movement; Neostriatum; Nerve Degeneration; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase; Weight Loss | 2000 |
Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Medulla; Animals; Antiparkinson Agents; Apomorphine; Capsules; Cattle; Chromaffin Cells; Disease Models, Animal; Dopamine; Female; Homovanillic Acid; Macaca mulatta; Microdialysis; Neostriatum; Parkinsonian Disorders; Stereotyped Behavior; Transplantation, Heterologous | 2000 |
Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system.
Topics: Animals; Antibodies; Apomorphine; Behavior, Animal; Cell Count; Corpus Striatum; Dopamine; Dopamine Agonists; Female; Glial Cell Line-Derived Neurotrophic Factor; Image Processing, Computer-Assisted; Microinjections; Nerve Degeneration; Nerve Fibers; Nerve Growth Factors; Nerve Tissue Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 2000 |
Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Corpus Striatum; Male; Nerve Degeneration; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Recovery of Function; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2001 |
IGF-I and bFGF improve dopamine neuron survival and behavioral outcome in parkinsonian rats receiving cultured human fetal tissue strands.
Topics: Abortion, Induced; Animals; Apomorphine; Brain; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Fibroblast Growth Factor 2; Homovanillic Acid; Humans; Insulin-Like Growth Factor I; Male; Methamphetamine; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Rotation; Transplantation, Heterologous; Tyrosine 3-Monooxygenase | 2001 |
Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence.
Topics: Amphetamine; Animals; Apomorphine; Atrophy; Axonal Transport; Corpus Striatum; Disease Models, Animal; Male; Motor Activity; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Vitamin E; Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate | 2001 |
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Apomorphine; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Macaca fascicularis; Neural Pathways; Neurons; Parkinsonian Disorders; Piribedil; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2001 |
Entopeduncular lesions facilitate and thalamic lesions depress spontaneous and drug-evoked motor behavior in the hemiparkinsonian rat.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Male; Motor Cortex; Neural Inhibition; Neural Pathways; Neurosurgical Procedures; Oxidopamine; Parkinsonian Disorders; Rats; Thalamus; Ventral Thalamic Nuclei | 2001 |
Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat.
Topics: Animals; Apomorphine; Benzazepines; Dopamine; Dopamine Agonists; Dopamine Antagonists; gamma-Aminobutyric Acid; Globus Pallidus; Male; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Recovery of Function; Sulpiride; Sympatholytics | 2001 |
Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Apomorphine; Dopamine; Dopamine Agonists; Drug Interactions; gamma-Aminobutyric Acid; Glutamic Acid; Iontophoresis; Male; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Dopamine D1; Substantia Nigra; Subthalamic Nucleus; Sympatholytics | 2001 |
Effects of isatin on rotational behavior and DA levels in caudate putamen in Parkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Biogenic Monoamines; Caudate Nucleus; Dopamine; Female; Isatin; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinsonian Disorders; Putamen; Rats; Rats, Wistar; Reference Values; Rotation; Stereotyped Behavior | 2001 |
Increased burst firing in substantia nigra pars reticulata neurons and enhanced response to selective D2 agonist in hemiparkinsonian rats after repeated administration of apomorphine.
Topics: Animals; Apomorphine; Dopamine Agonists; Male; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Substantia Nigra | 2001 |
Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
Topics: Animals; Apomorphine; Chromogranins; DNA, Complementary; Dopamine Agonists; Drug Administration Schedule; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Proteins; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Secretogranin II; Sympatholytics; Up-Regulation | 2001 |
Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Extremities; Female; Head; Motor Activity; Nerve Degeneration; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Tegmentum Mesencephali | 2001 |
Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Administration Routes; Male; Medial Forebrain Bundle; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Somatostatin | 2002 |
Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Line; Corpus Striatum; Dependovirus; Disease Models, Animal; Dopamine; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; Humans; Male; Medial Forebrain Bundle; Motor Activity; Nerve Growth Factors; Oxidopamine; Parkinsonian Disorders; Phenotype; Rats; Rats, Inbred F344; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Transplantation; Corpus Striatum; Dextrans; Dopamine; Fetal Tissue Transplantation; Graft Rejection; Humans; Male; Microspheres; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Pigment Epithelium of Eye; Random Allocation; Rats; Rats, Sprague-Dawley; Rotation; Transplantation, Heterologous | 2002 |